BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23920135)

  • 1. Predictive value of the smell identification test for nigrostriatal dopaminergic depletion in Korean tremor patients.
    Hong JY; Chung SJ; Lee JE; Sunwoo MK; Lee PH; Sohn YH
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1018-21. PubMed ID: 23920135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease.
    Kim HK; Kim T; Baek MS; Kim EY; Sung YH; Lee JH; Ryu YH; Ahn SJ; Yoo HS; Lyoo CH
    Eur J Neurol; 2023 Jun; 30(6):1639-1647. PubMed ID: 36915220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.
    Bohnen NI; Gedela S; Kuwabara H; Constantine GM; Mathis CA; Studenski SA; Moore RY
    J Neurol; 2007 Jan; 254(1):84-90. PubMed ID: 17508142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nigrostriatal dopaminergic function in subjects with isolated action tremor.
    Coria F; Gimenez-Garcia M; Samaranch L; Mora FJ; Sampol-Bas C; Pastor P
    Parkinsonism Relat Disord; 2012 Jan; 18(1):49-53. PubMed ID: 21917500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
    Happe S; Tings T; Koch W; Welsch J; Helmschmied K; Baier PC; Meller J; Wuttke W; Paulus W; Tatsch K; Trenkwalder C
    J Neural Transm (Vienna); 2007; 114(5):589-94. PubMed ID: 17187291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy.
    Hashimoto M; Kawasaki K; Suzuki M; Mitani K; Murayama S; Mishina M; Oda K; Kimura Y; Ishiwata K; Ishii K; Inoue K
    Neuroreport; 2008 Jan; 19(2):145-50. PubMed ID: 18185098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease.
    Lee JJ; Oh JS; Ham JH; Lee DH; Lee I; Sohn YH; Kim JS; Lee PH
    Neurobiol Aging; 2016 Feb; 38():197-204. PubMed ID: 26827658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
    Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
    Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
    Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
    Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography.
    Zheng HG; Zhang R; Li X; Li FF; Wang YC; Wang XM; Lu LL; Feng T
    Chin Med J (Engl); 2015 Jul; 128(13):1765-71. PubMed ID: 26112718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.